Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call

By The Northwire Desk — AI Analysis Mar 04, 2026 · 17:00 CPH · 14.86 CIPHER PHARMACEUTICALS INC.
CPH · Price

Executive Summary

  • Cipher Pharmaceuticals announced it will release its Q4 2025 and fiscal‑2025 financial results after market close on Thursday, March 12 2026.
  • A conference call to discuss the results and corporate developments is scheduled for Friday, March 13 2026 at 8:30 a.m. ET.
  • Call details (dial‑in numbers, replay code, webcast link) were provided for investors and analysts.

Key Details

  • Release Timing: Financial results will be posted after market close on Thursday, March 12 2026.
  • Conference Call:
  • Date: Friday, March 13 2026
  • Time: 8:30 a.m. ET
  • Dial‑in Numbers: 416‑945‑7677 or 888‑699‑1199 (U.S.)
  • Replay Access: 289‑819‑1450 or 888‑660‑6345, Code 29916#, expires March 20 2026.
  • Webcast URL: https://app.webinar.net/G7lE687Woew
  • Company Background (boilerplate removed): Cipher Pharmaceuticals is a specialty pharma company with products marketed in Canada, the U.S., and South America.

Notable Quotes

(No executive quotes were included in this release.)

Read the original news release →

More from CIPHER PHARMACEUTICALS INC.

May 07, 2026 · 17:00

Cipher Goes Debt-Free and Boasts $71M in Dry Powder, But Stagnant Sales Raise the Bar for Deal-Driven Growth

Earnings May 01, 2026 · 07:00

Cipher Pharmaceuticals NCIB Announcement

Other Mar 12, 2026 · 17:00

Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings

Earnings Jan 28, 2026 · 17:51

Cipher Pharmaceuticals gets Health Canada NDS review

Regulatory Jan 28, 2026 · 08:30

Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)

Regulatory Nov 06, 2025 · 17:00

Cipher Pharmaceuticals Reports Third Quarter 2025 Results

Earnings